U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H29N6O5P
Molecular Weight 476.4659
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TENOFOVIR ALAFENAMIDE

SMILES

CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)CN1C=NC2=C(N)N=CN=C12)OC3=CC=CC=C3

InChI

InChIKey=LDEKQSIMHVQZJK-CAQYMETFSA-N
InChI=1S/C21H29N6O5P/c1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27/h5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24)/t15-,16+,33+/m1/s1

HIDE SMILES / InChI

Molecular Formula C21H29N6O5P
Molecular Weight 476.4659
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/20439609 and http://ir.chimerix.com/releasedetail.cfm?releaseid=752310

CMX157 is a lipid (1-0-hexadecyloxypropyl) conjugate of the acyclic nucleotide analog tenofovir (TFV) with activity against both wild-type and antiretroviral drug-resistant HIV strains, including multidrug nucleoside/nucleotide analog-resistant viruses. CMX157 was designed to mimic lysophosphatidylcholine to take advantage of natural lipid uptake pathways and to achieve high intracellular concentrations of the active antiviral, with the aim of increasing the effectiveness of TFV against wild-type and mutant HIV. CMX157 demonstrated potential to effectively suppress replication of multiNRTI-resistant (MNR) HIV that cannot be treated with any currently available NRTIs, including TDF. It is in phase II clinical trial for HIV infections in USA and phase Ib portion of the phase I/II trial for Hepatitis B in Thailand (PO).

Originator

Curator's Comment: reference retrieved from http://www.sciencedirect.com/science/article/pii/S2211383512001402

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
58.0 µM [Kd]
3.3 nM [EC50]
3.5 nM [EC50]
0.49 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VIREAD

Approved Use

Tenofovir disoproxil fumarate is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV and HBV infections

Launch Date

1.32675836E12
Primary
VIREAD

Approved Use

Tenofovir disoproxil fumarate is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV and HBV infections

Launch Date

1.32675836E12
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine.
1993 Feb
Selective inhibition of HIV-1 reverse transcriptase by an antiviral inhibitor, (R)-9-(2-Phosphonylmethoxypropyl)adenine.
1998 Oct 16
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
2010 Jul
Patents

Sample Use Guides

The recommended dose of Ictady (tenofovir disoproxil succinate) for the treatment of HIV or for the treatment of chronic hepatitis B is 245 mg (one tablet) once daily taken orally with food.
Route of Administration: Oral
In Vitro Use Guide
(R)-9-(2-Phosphonylmethoxypropyl)adenine (PMPA known as tenofovir) exerts antiretrovirus activity in MT-4 cells infected with HIV-1 and HIV-2 with EC50 values of 5.9 and 4.9 uM, respectively
Substance Class Chemical
Created
by admin
on Sat Dec 16 06:04:36 UTC 2023
Edited
by admin
on Sat Dec 16 06:04:36 UTC 2023
Record UNII
EL9943AG5J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TENOFOVIR ALAFENAMIDE
DASH   INN   USAN   WHO-DD  
INN   USAN  
Official Name English
tenofovir alafenamide [INN]
Common Name English
TENOFOVIR ALAFENAMIDE [MI]
Common Name English
GS-734003
Code English
Tenofovir alafenamide [WHO-DD]
Common Name English
L-ALANINE, N-((S)-(((1R)-2-(6-AMINO-9H-PURIN-9-YL)-1-METHYLETHOXY)METHYL)PHENOXYPHOSPHINYL)-, 1-METHYLETHYL ESTER
Common Name English
GS-7340
Code English
1-METHYLETHYL N-((S)-(((1R)-2-(6-AMINO-9H-PURIN-9-YL)-1-METHYLETHOXY)METHYL)PHENOXYPHOSPHINYL)-L-ALANINATE
Systematic Name English
TENOFOVIR ALAFENAMIDE [USAN]
Common Name English
Classification Tree Code System Code
WHO-ATC J05AF13
Created by admin on Sat Dec 16 06:04:36 UTC 2023 , Edited by admin on Sat Dec 16 06:04:36 UTC 2023
EMA ASSESSMENT REPORTS GENVOYA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Sat Dec 16 06:04:36 UTC 2023 , Edited by admin on Sat Dec 16 06:04:36 UTC 2023
WHO-ATC J05AR19
Created by admin on Sat Dec 16 06:04:36 UTC 2023 , Edited by admin on Sat Dec 16 06:04:36 UTC 2023
EMA ASSESSMENT REPORTS DESCOVY (AUTHORIZED: HIV INFECTIONS )
Created by admin on Sat Dec 16 06:04:36 UTC 2023 , Edited by admin on Sat Dec 16 06:04:36 UTC 2023
WHO-ATC J05AR22
Created by admin on Sat Dec 16 06:04:36 UTC 2023 , Edited by admin on Sat Dec 16 06:04:36 UTC 2023
FDA ORPHAN DRUG 569716
Created by admin on Sat Dec 16 06:04:36 UTC 2023 , Edited by admin on Sat Dec 16 06:04:36 UTC 2023
WHO-ATC J05AR18
Created by admin on Sat Dec 16 06:04:36 UTC 2023 , Edited by admin on Sat Dec 16 06:04:36 UTC 2023
NCI_THESAURUS C97452
Created by admin on Sat Dec 16 06:04:36 UTC 2023 , Edited by admin on Sat Dec 16 06:04:36 UTC 2023
NCI_THESAURUS C281
Created by admin on Sat Dec 16 06:04:36 UTC 2023 , Edited by admin on Sat Dec 16 06:04:36 UTC 2023
WHO-ATC J05AR20
Created by admin on Sat Dec 16 06:04:36 UTC 2023 , Edited by admin on Sat Dec 16 06:04:36 UTC 2023
Code System Code Type Description
DRUG CENTRAL
4944
Created by admin on Sat Dec 16 06:04:36 UTC 2023 , Edited by admin on Sat Dec 16 06:04:36 UTC 2023
PRIMARY
WIKIPEDIA
Tenofovir alafenamide
Created by admin on Sat Dec 16 06:04:36 UTC 2023 , Edited by admin on Sat Dec 16 06:04:36 UTC 2023
PRIMARY
INN
9980
Created by admin on Sat Dec 16 06:04:36 UTC 2023 , Edited by admin on Sat Dec 16 06:04:36 UTC 2023
PRIMARY
CAS
379270-37-8
Created by admin on Sat Dec 16 06:04:36 UTC 2023 , Edited by admin on Sat Dec 16 06:04:36 UTC 2023
PRIMARY
ChEMBL
CHEMBL2107825
Created by admin on Sat Dec 16 06:04:36 UTC 2023 , Edited by admin on Sat Dec 16 06:04:36 UTC 2023
PRIMARY
FDA UNII
EL9943AG5J
Created by admin on Sat Dec 16 06:04:36 UTC 2023 , Edited by admin on Sat Dec 16 06:04:36 UTC 2023
PRIMARY
EVMPD
SUB121761
Created by admin on Sat Dec 16 06:04:36 UTC 2023 , Edited by admin on Sat Dec 16 06:04:36 UTC 2023
PRIMARY
CHEBI
90926
Created by admin on Sat Dec 16 06:04:36 UTC 2023 , Edited by admin on Sat Dec 16 06:04:36 UTC 2023
PRIMARY
SMS_ID
100000144893
Created by admin on Sat Dec 16 06:04:36 UTC 2023 , Edited by admin on Sat Dec 16 06:04:36 UTC 2023
PRIMARY
DRUG BANK
DB09299
Created by admin on Sat Dec 16 06:04:36 UTC 2023 , Edited by admin on Sat Dec 16 06:04:36 UTC 2023
PRIMARY
RXCUI
1721603
Created by admin on Sat Dec 16 06:04:36 UTC 2023 , Edited by admin on Sat Dec 16 06:04:36 UTC 2023
PRIMARY RxNorm
DAILYMED
EL9943AG5J
Created by admin on Sat Dec 16 06:04:36 UTC 2023 , Edited by admin on Sat Dec 16 06:04:36 UTC 2023
PRIMARY
NCI_THESAURUS
C148276
Created by admin on Sat Dec 16 06:04:36 UTC 2023 , Edited by admin on Sat Dec 16 06:04:36 UTC 2023
PRIMARY
USAN
ZZ-65
Created by admin on Sat Dec 16 06:04:36 UTC 2023 , Edited by admin on Sat Dec 16 06:04:36 UTC 2023
PRIMARY
MERCK INDEX
m12126
Created by admin on Sat Dec 16 06:04:36 UTC 2023 , Edited by admin on Sat Dec 16 06:04:36 UTC 2023
PRIMARY
EPA CompTox
DTXSID50958941
Created by admin on Sat Dec 16 06:04:36 UTC 2023 , Edited by admin on Sat Dec 16 06:04:36 UTC 2023
PRIMARY
PUBCHEM
9574768
Created by admin on Sat Dec 16 06:04:36 UTC 2023 , Edited by admin on Sat Dec 16 06:04:36 UTC 2023
PRIMARY
Related Record Type Details
TRANSPORTER -> SUBSTRATE
ENANTIOMER -> ENANTIOMER
METABOLIC ENZYME -> SUBSTRATE
BINDER->LIGAND
BINDING
TRANSPORTER -> SUBSTRATE
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> SUBSTRATE
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
METABOLITE ACTIVE -> PRODRUG
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC